Because of confidentiality agreements, the identities on the trial individuals continue to be undisclosed. Eli Lilly, the pharmaceutical firm driving retatrutide, declined to comment on the protocols of its ongoing trials but mentioned that patient safety can be a priority.The value hasn't been announced because it continues to be in improvement an